Carl Zeiss Meditec AG has successfully placed 8,130,960 new shares (around 10 %) by way of an accelerated bookbuilding process with the exclusion of subscription rights with selected domestic and international institutional investors. The gross proceeds amounted to a total of around EUR 317 m. The TecDAX-listed company Carl Zeiss Meditec AG is one of the world’s leading medical technology companies in the fields of ophthalmology and microsurgery.
Hengeler Mueller advised Carl Zeiss Meditec AG on the transaction. The Hengeler Mueller team included partners Wolfgang Groß (Capital Markets, Frankfurt) and Georg Seyfarth (M&A/Corporate, Düsseldorf) as well as associate Johannes Honzen (Capital Markets, Frankfurt/London).
